Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
Olivier HumbertGeorge S LaszloSophie SichelChristina IronsideKevin G HaworthOlivia M BatesMary E BeddoeRay R CarrilloHans-Peter KiemRoland Bruno WalterPublished in: Leukemia (2018)